16,284 resources
Start Prev Rows 7000 - 7200 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date |
|---|---|---|---|---|---|---|---|
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1072 | Miosis (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1076 | Opioid Overdose and Poisoning (Tests for Opioids [Quantitative]) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1083 | Rash [Pustular Vesicular] (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1084 | Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1090 | Syphilis [Congenital] (Disorders) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1091 | Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1092 | Congenital heart disease (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1093 | Hearing impairment (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1095 | Microcephaly (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1096 | Developmental delay (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1099 | Congenital heart disease (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1100 | Hearing impairment (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1104 | Developmental delay (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1106 | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.112 | Tetanus (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1130 | Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1131 | Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassay | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1138 | Staphylococcus Aureus (Tests by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1139 | VISA/VRSA (Tests for Vancomycin Resistance Gene) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1145 | Resistant Lab Result Value | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1148 | Tests for Vancomycin Susceptibility [Ord] | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1149 | Proteinuria (Tests for Total Protein in 24H Urine) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.115 | Mumps (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1150 | Thrombocytopenia (Tests for Platelets [#/volume] in Blood) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1156 | Staphylococcus aureus (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1169 | Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.117 | Mumps (Disorders) (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1180 | Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative]) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1186 | Eastern Equine Encephalitis Virus Disease (Tests for Eastern Equine Encephalitis Virus Antibody [Qualitative]) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1188 | Western Equine Encephalitis Virus Disease (Tests for Western Equine Encephalitis Virus Antibody [Qualitative]) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1196 | Anthrax (Tests for Bacillus cereus by Culture and Identification Method) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1197 | Cervical Lymphadenitis (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1207 | CRE (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1212 | Enterobacteriaceae species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1213 | NU_Enterobacteriaceae [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1214 | Carbapenemase resistance mechanism (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1215 | Tests for carbapenemase production | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1216 | Tests for carbapenemase resistance mechanism | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1217 | Tests for carbapenem susceptibility [Meropenem, imipenem, and doripenem] | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1218 | Tests for carbapenem susceptibility [Ertapenem] | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1219 | Tests for Enterobacter spp., E. coli, or Klebsiella spp. by Culture and Identification Method | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1220 | NU_Tests for Enterobacteriaceae species by Culture and Identification Method | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1224 | Therapeutic Response to Medication [Improved] | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1225 | Altered Mental Status (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1230 | Eschar (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1231 | Hypotension (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1233 | Localized Edema (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1234 | Localized Edema (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1237 | Tachycardia (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1238 | Tachycardia (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1239 | RCKMS Conditions (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.124 | Poliomyelitis (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1240 | Maternal Condition Puerperium (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1242 | Non pestis Yersiniosis Infection (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1244 | Blastomycosis (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1246 | Blastomycosis (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1249 | Blastomycosis (Tests for Blastomyces species by Culture and Identification Method) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1250 | Non pestis Yersiniosis Infection (Tests for Yersinia non pestis species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1251 | Blastomycosis (Tests for Blastomyces species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1252 | Blastomycosis (Tests for Blastomyces species Antibody) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1253 | Blastomycosis (Tests for Blastomyces species Antigen) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1265 | Fatigue (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1269 | Tuberculosis [Latent Infection] (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1274 | Histoplasmosis (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1275 | Histoplasmosis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1281 | Histoplasmosis (Tests for Histoplasma capsulatum H band or M band Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1294 | Abscess [Liver, Lung, Spleen, Prostate, or Brain] (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1295 | Seizure [Unspecified Cause] (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1298 | Abscess [Liver, Lung, Spleen, Prostate, or Brain] (ICD10CM) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1299 | Seizure [Unspecified Cause] (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.130 | Influenza (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1304 | Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species in Extrapulmonary Specimen by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1305 | Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species Nucleic Acid in Extrapulmonary Specimen) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1306 | Body Temperature (Vital Sign) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1307 | Respiratory Rate (Vital Sign) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1309 | RSV (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1310 | RSV (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1312 | RSV (Tests for RSV Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1314 | Wheezing (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1317 | Bronchiolitis (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1325 | Tobacco Use and Exposure (Social History) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1330 | Tobacco Smoking Status [Current] (Social History) (LOINC) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1335 | Hospitalized [Inpatient] (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1336 | Creutzfeldt Jakob Disease (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1337 | Variant Creutzfeldt Jakob Disease (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1340 | Prion Disease (Tests for 14_3_3 Protein) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1341 | Prion Disease (Tests for Abnormal Prion Protein) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1349 | Cerebrospinal Fluid (Specimen Type) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.135 | Chronic Hepatitis B Virus Infection (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1350 | Endocervical (Specimen Type) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1351 | Tissue (Specimen Type) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1352 | Specimen from a Normally Sterile Site (Specimen Type)(SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1353 | Urethral Swab (Specimen Type) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1355 | Wound (Specimen Type) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1359 | Hepatitis E (Tests for hepatitis E virus IgM Antibody) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.136 | Invasive Pneumococcal Disease (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1360 | Hepatitis E (Tests for hepatitis E virus Antibody) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1363 | Epiglottitis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1364 | Organisms (Tests by Microscopic Observation by Gram Stain) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1369 | Serum (Specimen Type) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1378 | Tests for Mycobacterium species Nucleic Acid in Unspecified XXX Specimen | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1379 | Fish Poisoning (Disorders) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1388 | Occupational Asthma (Disorders) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1389 | Asthma (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1390 | Asthma (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1391 | Respiratory Condition, due to inhalation of chemicals, gases, fumes or vapors (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1393 | WRA (Occupational Exposure to Potential Asthma Inducing Risk Factor) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1400 | Colorado tick fever (Tests for Colorado Tick Fever Virus Antibody [Qualitative]) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1402 | Cancer [Malignant Neoplasms] (Disorders) (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1403 | Cancer [Benign or Borderline CNS Tumors] (Disorders) (ICD10CM) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1404 | Cancer [Unspecified Skin Cancer, Benign Carcinoid Tumor, in situ Cervical Cancer, Intraepithelial Neoplasia, History Cancer, Complication of Cancer or Treatment] (Disorders) (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1405 | Cancer [Unspecified Skin Cancer, Benign Carcinoid Tumor, in situ Cervical Cancer, Intraepithelial Neoplasia, History Cancer, Complication of Cancer or Treatment] (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1407 | Cancer [Malignant Neoplasms] (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1418 | Alpha gal syndrome (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1420 | Alpha gal syndrome (Tests for Alpha gal IgE Antibody [Quantitative]) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1422 | Ptosis of Eyelid [Unspecified Cause] (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1423 | Ptosis of Eyelid [Unspecified Cause] (ICD10CM) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1424 | Constipation [Unspecified Cause] (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1426 | Intubation [Respiratory Tract] (Procedure) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1430 | Infant Botulism (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1446 | Viral Hemorrhagic Fever [Suspected] (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1447 | MRSA (Disorders (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1449 | Staphylococcus aureus infection (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.145 | Varicella (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1450 | Staphylococcus aureus infection (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1452 | MRSA (Tests by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1453 | MRSA (Tests for Methicillin Resistance Gene) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1454 | Staphylococcus aureus (Tests for Staph aureus Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1458 | Tests for Cefoxitin Susceptibility [OrdQn] | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1459 | Organisms (Tests in Blood by Culture and Identification) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1460 | Bacteria (Tests in Blood by Culture and Identification Method) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1461 | Organisms (Tests in Specimen from Normally Sterile Site by Culture and Identification) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1462 | Staphylococcus aureus (Tests for Staph aureus Nucleic Acid in Blood) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1463 | VRE (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1464 | VRE (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1465 | VRE (Tests by Culture and Identification Method) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1466 | Enterococcus species (Tests by Culture and Identification Method) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1468 | Enterococcus gallinarum or E. casseliflavus/E. flavescens (Organism or Substance in Lab Results) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1469 | Enterococcus faecium or E. faecalis (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1470 | Enterococcus species (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1471 | Amebiasis (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1473 | Amebiasis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1476 | Amebiasis (Tests for Entamoeba histolytica Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1482 | Norovirus (Tests for Norovirus Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1485 | Norovirus (Organism or Substance in Lab Results) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1487 | Clostridioides difficile infection (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1491 | C. diff infection (Tests for C diff Toxin Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1492 | C. diff infection (Tests for C diff Toxin Nucleic Acid in Stool) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1505 | Acanthamoeba Disease [Keratitis] (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1507 | Arsenic Exposure and Toxicity (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1509 | Arsenic Exposure and Toxicity (Tests for Arsenic [Quantitative] in Unspecified Specimen) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1513 | Urine (Specimen Type) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1514 | Mercury Exposure and Toxicity (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1515 | Cryptococcosis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1516 | Cryptococcosis (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1520 | Cryptococcosis (Tests for Cryptococcus species by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1523 | Cryptococcosis (Tests for Cryptococcus species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1524 | Cryptococcosis (Tests for Cryptococcus species Antigen) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1525 | Mercury Exposure and Toxicity (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1528 | Mercury Exposure and Toxicity (Tests for Mercury [Quantitative] in Unspecified Specimen) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1532 | Drug Overdose and Poisoning [Non opioid] [CNS Stimulant] (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1533 | Drug Overdose and Poisoning [Non opioid] [CNS Depressant] (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1534 | Drug Overdose and Poisoning [Non opioid] [Cannabinoid] (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1538 | Drug Overdose and Poisoning [Non opioid] [Other Drug] (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.154 | Hepatitis C Virus Infection (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1540 | Drug Overdose and Poisoning [Non opioid] [CNS Stimulant] (Disorders) (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1541 | Drug Overdose and Poisoning [Non opioid] [CNS Depressant] (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1542 | Drug Overdose and Poisoning [Non opioid] [Hallucinogen] (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1543 | Drug Overdose and Poisoning [Non opioid] [Cannabinoid] (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1544 | Drug Overdose and Poisoning [Non opioid] [Analgesic] (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1545 | Drug Overdose and Poisoning [Non opioid] [Other Drug] (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1546 | Drug Overdose and Poisoning [Non opioid] (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1551 | Meningitis (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1552 | Bacterial Meningitis (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1553 | Fungal Meningitis (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1554 | Parasitic Meningitis (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1555 | Bacterial Meningitis (Disorders) (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1559 | Photophobia (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1562 | Bacteria [Causing Meningitis] (Organism or Substance in Lab Results) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1563 | Fungi [Causing Meningitis and Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1564 | Viruses [Causing Meningitis] (Organism or Substance in Lab Results) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1565 | Viruses [Causing Meningitis] (Tests for Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1566 | Viruses [Causing Meningitis] (Tests for Nucleic Acid in Cerebrospinal Fluid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1567 | Bacteria [Causing Meningitis] (Tests by Culture and Identification Method) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1574 | Invasive Group B Streptococcus (Disorders) (ICD10CM)) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1577 | Group A Streptococcus (Tests for Group A Strep by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1578 | Group B Streptococcus (Tests for Group B Strep by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1580 | Animal Bite [Dog] (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1581 | Animal Bite [Mammal, Excluding Dogs] (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1582 | Animal Bite [Excluding Mammals] (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1584 | Animal Bite [Unspecified Animal] (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1585 | Animal Bite [Dog] (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1586 | Animal Bite [Mammal, Excluding Dogs] (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1587 | Animal Bite [Excluding Mammals] (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1588 | Cadmium Exposure and Toxicity (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1604 | Vaccine Adverse Event (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1605 | Vaccine Adverse Event (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1606 | Vaccinia disease or adverse event (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.161 | Vibriosis (Disorders) (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.1612 | Blepharitis [Unspecified Cause] (ICD10CM) | active | 2024-06 |
FHIR